09:59 AM EDT, 03/26/2025 (MT Newswires) -- Exelixis ( EXEL ) said Wednesday it received approval for Cabometyx for patients with previously treated advanced neuroendocrine tumors from the US Food and Drug Administration.

The approval was for the treatment of patients 12 years of age and older with previously treated, unresectable, pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

The company said the approval was based on a phase 3 trial that showed a statistically significant and clinically meaningful improvement in progression-free survival in patients with the treatment compared with those with a placebo.

Price: 37.41, Change: -0.30, Percent Change: -0.81